Dulaglutide (Trulicity): Weight Loss as a Side Benefit

GLP-1 Receptor Agonist Classes

4.6 kg weight loss

In the SUSTAIN 7 head-to-head trial, dulaglutide 1.5 mg produced 3.0 kg weight loss compared to 6.5 kg with semaglutide 1.0 mg, a clinically meaningful but smaller effect.

Pratley et al., The Lancet Diabetes & Endocrinology, 2018

Pratley et al., The Lancet Diabetes & Endocrinology, 2018

View as image

Dulaglutide (Trulicity) is the GLP-1 receptor agonist that does not make headlines. It is not semaglutide with its cultural moment. It is not tirzepatide with its dual-receptor novelty. It is a once-weekly GLP-1 RA that has been prescribed to millions of patients worldwide since 2014, primarily for type 2 diabetes, with weight loss as a secondary outcome rather than the primary indication. This positioning obscures a useful clinical profile. Dulaglutide produces consistent, moderate weight loss (3-6 kg depending on dose), has the largest cardiovascular outcomes dataset of any GLP-1 RA through the REWIND trial, and in real-world practice has demonstrated better adherence rates than some competitors partly because of its ready-to-use pen design. Understanding where dulaglutide fits in the GLP-1 landscape requires separating what it was designed to do from what patients now expect GLP-1 drugs to deliver. For a comparison of how short-acting and long-acting GLP-1 agonists differ, see the pillar article.

What Dulaglutide Is

Dulaglutide is a GLP-1 receptor agonist designed for once-weekly subcutaneous injection. Its structure differs from semaglutide in a pharmacologically important way. Where semaglutide uses a fatty acid side chain (lipidation) to bind albumin and extend its half-life, dulaglutide is a fusion protein: two GLP-1 analog molecules linked to a modified human IgG4 Fc fragment. This immunoglobulin backbone gives dulaglutide a half-life of approximately 5 days, enabling once-weekly dosing.

The GLP-1 analog component is modified from native GLP-1 to resist degradation by DPP-4, the enzyme that breaks down endogenous GLP-1 in minutes. Specific substitutions (Gly8Ala, Gly36Gly modification) protect the DPP-4 cleavage site while maintaining receptor binding.

Approved doses are 0.75 mg and 1.5 mg weekly for type 2 diabetes. Higher doses of 3.0 mg and 4.5 mg were tested in the AWARD-11 trial and are approved in some markets for additional glycemic control. Dulaglutide does not have an FDA-approved indication for weight management in patients without diabetes, a key distinction from semaglutide 2.4 mg (Wegovy).

The AWARD Trials: Weight Loss Data

The AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) clinical program includes 11 Phase III trials testing dulaglutide across multiple diabetes treatment settings.

AWARD-1: Dulaglutide 1.5 mg versus exenatide twice daily: weight loss of 1.3 kg with dulaglutide versus 1.1 kg with exenatide at 26 weeks. Modest, comparable to the first-generation GLP-1 RA.

AWARD-6: Dulaglutide 1.5 mg versus liraglutide 1.8 mg (head-to-head with the previous generation's leading drug): weight loss was similar between groups at approximately 3 kg over 26 weeks.

AWARD-11: Dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg: the higher doses produced additional weight loss. At 36 weeks, mean weight loss was approximately 4.0 kg with 3.0 mg and 5.0 kg with 4.5 mg, compared to 3.1 kg with 1.5 mg. The higher doses were not tested against semaglutide.

Bobu et al. (2025) confirmed these findings in a Romanian real-world cohort: dulaglutide 1.5 mg significantly improved glycemic control while reducing LDL cholesterol and body weight, with weight loss as a consistent secondary benefit across diverse patients.^[6]

SUSTAIN 7: The Head-to-Head With Semaglutide

The trial that defines dulaglutide's weight loss positioning is SUSTAIN 7 (Pratley et al., Lancet Diabetes & Endocrinology, 2018), which directly compared once-weekly semaglutide with once-weekly dulaglutide in 1,201 patients with type 2 diabetes over 40 weeks.

Low-dose comparison: Semaglutide 0.5 mg produced 4.6 kg weight loss versus 2.3 kg with dulaglutide 0.75 mg (difference: 2.3 kg favoring semaglutide).

High-dose comparison: Semaglutide 1.0 mg produced 6.5 kg weight loss versus 3.0 kg with dulaglutide 1.5 mg (difference: 3.5 kg favoring semaglutide).

Semaglutide approximately doubled dulaglutide's weight loss at both dose levels. For glycemic control, semaglutide was also superior, reducing HbA1c by 1.5-1.8% versus 1.1-1.4% for dulaglutide.

An indirect treatment comparison found that even the higher dulaglutide doses (3.0 and 4.5 mg, tested in AWARD-11 but not head-to-head with semaglutide) would likely produce less weight loss than semaglutide 1.0 mg, with estimated differences of 2.65 kg and 1.95 kg respectively favoring semaglutide.

Xie et al. (2026) confirmed these findings in a Chinese real-world population: semaglutide produced greater reductions in HbA1c, body weight, and BMI than dulaglutide across multiple clinical endpoints.^[3]

Real-World Weight Loss Data

Clinical trials enroll selected patients with specific inclusion criteria. Real-world data reveals how drugs perform in the broader population.

Derington et al. (2025) compared liraglutide, semaglutide, and dulaglutide in U.S. veterans with type 2 diabetes, the largest real-world GLP-1 RA comparison to date. At 12 months, semaglutide produced 5.0% body weight reduction versus 3.1% for dulaglutide. However, dulaglutide showed higher medication adherence, likely reflecting its pre-filled, ready-to-use pen design (no needle attachment required) and its longer market presence with better prescriber familiarity.^[5]

Alonazi et al. (2025) studied dulaglutide specifically for weight reduction in Saudi Arabian diabetic patients. Mean weight loss was 5.63 kg (5.83% of baseline weight), consistent with the higher end of clinical trial results, possibly reflecting the population's higher baseline BMI and greater room for pharmacological weight reduction.^[4]

The REWIND Cardiovascular Advantage

The REWIND trial (n=9,901) is the largest cardiovascular outcomes trial of any GLP-1 RA. It enrolled a broader population than other CVOTs: only 31% of participants had established cardiovascular disease at baseline, compared to 73-83% in the semaglutide (SUSTAIN 6) and liraglutide (LEADER) trials. This matters because it demonstrates cardiovascular benefit in primary prevention (patients at risk but without prior events), not just secondary prevention.

Key REWIND results:

• 12% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke)
• 32% reduction in new or worsening nephropathy
• Mean follow-up of 5.4 years, longer than most GLP-1 CVOTs
• Benefits observed at the 1.5 mg dose (the standard diabetes dose, not a higher weight-management dose)

Bonnesen et al. (2025) compared the cardiovascular effectiveness of semaglutide versus dulaglutide in type 2 diabetes in a real-world population study, finding different risk profiles depending on the outcome examined.^[7] Tan et al. (2026) similarly compared cardiovascular outcomes between semaglutide and dulaglutide in a large observational cohort.^[9]

Gastrointestinal Tolerability

A common clinical consideration in GLP-1 RA selection is gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are the primary reason patients discontinue GLP-1 therapy.

Crisafulli et al. (2026) published a comparative gastrointestinal safety analysis of dulaglutide, semaglutide, and tirzepatide in the Annals of Internal Medicine. Among the three, dulaglutide had the most favorable GI safety profile, with lower rates of nausea, vomiting, and treatment discontinuation due to GI adverse events.^[1]

This finding aligns with clinical experience. Dulaglutide's GLP-1 analog is fused to a large IgG4 Fc fragment, which may slow its entry into the central nervous system where GLP-1 receptors in the area postrema trigger nausea. The slower onset and lower peak receptor activation compared to the smaller, albumin-binding semaglutide molecule could explain the GI tolerability advantage.

For patients who cannot tolerate semaglutide's GI side effects, dulaglutide offers the same drug class with potentially better tolerability, albeit at the cost of less weight loss.

Beyond Weight: Kidney and Metabolic Effects

McFarlin et al. (2026) reported that dulaglutide modulated proteins associated with CKD progression, suggesting renoprotective mechanisms beyond weight loss and glycemic control. This finding, combined with REWIND's 32% reduction in nephropathy, positions dulaglutide as a GLP-1 RA with demonstrated kidney benefits.^[8]

Ostrominski et al. (2026) compared the cardiovascular effectiveness of tirzepatide versus dulaglutide or semaglutide in a large observational study, providing the first real-world comparison of the dual agonist against both single-target GLP-1 RAs.^[2]

Where Dulaglutide Fits in 2026

Dulaglutide occupies a specific clinical niche:

Primary indication: type 2 diabetes. Dulaglutide remains a first-line GLP-1 RA for glycemic control. It is not prescribed primarily for weight loss.

Cardiovascular protection. REWIND provides the strongest evidence for primary cardiovascular prevention among GLP-1 RAs. Patients with type 2 diabetes and cardiovascular risk factors (but without established disease) have the best evidence base with dulaglutide.

GI-sensitive patients. Those who cannot tolerate semaglutide or tirzepatide may do well on dulaglutide with its more favorable GI profile.

Moderate weight loss expectations. Patients seeking 3-6 kg weight loss as a component of diabetes management, rather than 15-20% total body weight loss, may find dulaglutide achieves their goals with fewer side effects.

Cost and access. In markets where semaglutide faces supply constraints or formulary restrictions, dulaglutide provides a proven alternative within the same drug class.

Dulaglutide is not the most potent GLP-1 RA for weight loss. That title belongs to semaglutide 2.4 mg, and tirzepatide may exceed even that. But potency is one dimension of a clinical decision that includes tolerability, cardiovascular evidence, renal protection, adherence, and cost. For a comprehensive overview comparing every GLP-1 receptor agonist across all these dimensions, see the dedicated comparison article. For background on the history of GLP-1 drugs and how dulaglutide emerged from the drug development pipeline, see the history article. For the original GLP-1 that started it all, see Exenatide (Byetta/Bydureon).

The Bottom Line

Dulaglutide produces consistent but moderate weight loss of 3-6 kg, approximately half what semaglutide achieves at comparable doses. Its clinical value lies beyond weight: the REWIND trial demonstrated cardiovascular protection in a broader population than any other GLP-1 RA CVOT, with a 12% reduction in MACE and 32% reduction in nephropathy. A 2026 comparative safety analysis found dulaglutide has a more favorable GI side effect profile than semaglutide or tirzepatide. In real-world practice, dulaglutide shows higher adherence rates, likely due to its user-friendly pen design. It is not the drug for patients seeking maximum weight loss, but it fills a legitimate role for patients prioritizing glycemic control, cardiovascular protection, and tolerability.

Frequently Asked Questions

How much weight can you lose on dulaglutide?

In clinical trials, dulaglutide 1.5 mg produces approximately 3.0 kg weight loss at 40 weeks. Higher doses (3.0 mg and 4.5 mg, tested in AWARD-11) produce 4.0-5.0 kg at 36 weeks. Real-world data from Saudi Arabian patients showed 5.63 kg mean weight loss (5.83% of baseline). In the SUSTAIN 7 head-to-head trial, semaglutide 1.0 mg produced approximately double the weight loss of dulaglutide 1.5 mg (6.5 kg vs 3.0 kg). Dulaglutide is not approved for weight management in patients without diabetes.

Is dulaglutide or semaglutide better for weight loss?

Semaglutide produces greater weight loss at every dose level tested. In the SUSTAIN 7 trial, semaglutide 1.0 mg achieved 6.5 kg weight loss versus 3.0 kg for dulaglutide 1.5 mg. Real-world U.S. data confirmed this: semaglutide produced 5.0% body weight loss versus 3.1% for dulaglutide at 12 months. However, dulaglutide has a more favorable GI side effect profile (less nausea and vomiting), higher real-world adherence, and the broadest cardiovascular outcomes evidence through the REWIND trial.

Does Trulicity help you lose belly fat?

Dulaglutide reduces body weight including visceral (belly) fat, though specific DXA body composition data for dulaglutide is more limited than for semaglutide. In the STEP 1 DXA substudy of semaglutide, visceral fat reduction was disproportionately large (27.4% reduction). As a drug that works through the same GLP-1 receptor, dulaglutide likely produces a similar preferential visceral fat reduction pattern, though at a smaller magnitude given its lower overall weight loss.

Can dulaglutide be prescribed for weight loss?

Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes management only. It does not have an approved indication for weight management in patients without diabetes, unlike semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound). Off-label prescribing for weight loss does occur, but insurance coverage is typically limited to the diabetes indication. For patients with type 2 diabetes, weight loss is a well-documented and welcome secondary benefit of dulaglutide therapy.

Does dulaglutide have fewer side effects than semaglutide?

A 2026 comparative analysis in the Annals of Internal Medicine found dulaglutide had a more favorable gastrointestinal safety profile than both semaglutide and tirzepatide, with lower rates of nausea, vomiting, and GI-related treatment discontinuation (Crisafulli et al., 2026). This may relate to dulaglutide's larger molecular size and IgG4 Fc fusion design, which could slow central nervous system penetration where nausea-triggering GLP-1 receptors are located.

What is the REWIND trial for Trulicity?

REWIND was a cardiovascular outcomes trial that enrolled 9,901 patients with type 2 diabetes and followed them for a median of 5.4 years, the longest follow-up of any GLP-1 RA CVOT. Unlike other trials that enrolled mostly patients with established cardiovascular disease, REWIND included 69% of patients without prior cardiovascular events. Results showed dulaglutide reduced major cardiovascular events by 12% and new or worsening nephropathy by 32%, demonstrating cardiovascular and renal benefits in primary prevention.